 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Largest Trial of EGFR-Mutated NSCLC Patients Promises New Personalized Treatment Option
June 06, 2012
Largest Trial of EGFR-Mutated NSCLC Patients Promises New Personalized Treatment Option
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Boehringer Launches 'Let's Test' Campaign to Educate Healthcare Providers on NSCLC Biomarker Testing
October 24, 2012 / Pharmacogenomics Reporter - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
January 16, 2013 / Pharmacogenomics Reporter - Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M
May 26, 2010 / Pharmacogenomics Reporter - Boehringer Ingelheim to Present New Data on PGx NSCLC Drug Afatinib at ASCO Annual Meeting
June 1, 2011 / Pharmacogenomics Reporter